James Geraghty
Overview
Explore the profile of James Geraghty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frazer K, Bhardwaj N, Fox P, Lyons A, Syed S, Niranjan V, et al.
Nicotine Tob Res
. 2024 Jul;
27(2):199-207.
PMID: 39037899
Introduction: Despite the benefits of quitting smoking for those who have cancer, including improved health outcomes and reduced therapeutic toxicities, it is unclear how many people are supported in quit...
2.
Zaborowski A, Doogan K, Clifford S, Dowling G, Kazi F, Delaney K, et al.
Br J Surg
. 2023 Dec;
111(1).
PMID: 38055888
Background: The necessity of performing a sentinel lymph node biopsy in patients with clinically and radiologically node-negative breast cancer after neoadjuvant chemotherapy has been questioned. The aim of this study...
3.
Kuzmova M, Cullinane C, Rutherford C, McCartan D, Rothwell J, Evoy D, et al.
Surg Oncol
. 2023 Nov;
51:102011.
PMID: 37931546
Background: Pathological complete response (pCR) following neo-adjuvant chemotherapy (NACT) for breast cancer is associated with improved disease-free and overall survival in certain breast cancer subtypes. Magnetic Resonance Imaging (MRI) is...
4.
Zaborowski A, Roe S, Rothwell J, Evoy D, Geraghty J, McCartan D, et al.
J Surg Oncol
. 2022 Oct;
127(3):361-368.
PMID: 36208279
Nipple-sparing mastectomy is an alternative to skin-sparing mastectomy in select patients. Increasing evidence supports its use in the setting of breast cancer, however concerns still exist regarding oncological safety. The...
5.
Shrestha A, Cullinane C, Evoy D, Geraghty J, Rothwell J, Walshe J, et al.
Br J Surg
. 2022 Feb;
109(5):411-417.
PMID: 35194632
Background: The Clinical Treatment Score post-5 years (CTS5) integrates four clinicopathological variables to estimate the residual disease recurrence risk in hormone receptor-positive breast cancer patients who have been treated with...
6.
Cullinane C, Gillan H, Geraghty J, Evoy D, Rothwell J, McCartan D, et al.
BJS Open
. 2022 Feb;
6(1).
PMID: 35143625
Background: The significance of exogenous hormone manipulation as part of fertility treatment and its relationship to the development of breast cancer remains uncertain. Several historical reviews have been performed with...
7.
Cullinane C, Shrestha A, Al Maksoud A, Rothwell J, Evoy D, Geraghty J, et al.
Eur J Surg Oncol
. 2021 Feb;
47(7):1507-1513.
PMID: 33589241
Background: Administration of chemotherapy before breast surgery has the potential to reduce the risk of distant recurrence by targeting micrometastasis as well as allowing a more minimalistic approach to surgical...
8.
Balasubramanian I, Harding T, Boland M, Ryan E, Geraghty J, Evoy D, et al.
Clin Breast Cancer
. 2021 Jan;
21(4):e377-e387.
PMID: 33451964
The association between immediate breast reconstruction (IBR)-related wound complications and breast cancer recurrence (BCR) remains uncertain. This study aimed to investigate the oncological outcomes in patients with wound complications following...
9.
Boland M, Nugent T, Nolan J, OMahony J, OKeeffe S, Gillham C, et al.
Breast Cancer
. 2020 Aug;
28(1):168-174.
PMID: 32780320
Background: Breast fibromatosis is a rare clinical entity, but poses significant diagnostic and therapeutic challenges. In light of recent changes in management practices, the aim was to review our institutional...
10.
Boland M, Heneghan H, Ryan E, Ain Q, Skehan S, McCartan D, et al.
Breast J
. 2020 Feb;
26(7):1452-1454.
PMID: 32091643
No abstract available.